Literature DB >> 18551720

Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma.

Aggeliki Kolialexi1, George Th Tsangaris, Nikos Papantoniou, Athanasios K Anagnostopoulos, Kostantinos Vougas, Vassilis Bagiokos, Aris Antsaklis, Ariadni Mavrou.   

Abstract

BACKGROUND: Despite the large impact of ultrasonographic and biochemical markers on prenatal screening, the ability to accurately diagnose Down syndrome (DS) is still limited and better diagnostic testing is needed.
METHODS: Plasma from 8 women carrying a DS foetus and 12 with non-DS foetuses matched for gestational age, maternal age and ethnicity, in the second trimester of pregnancy, was analysed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in order to identify biomarkers for DS.
RESULTS: Gel comparison revealed nine proteins differentially expressed in maternal plasma in women with DS foetuses. Eight proteins, transthyretin (TTHY), ceruloplasmin (CERU), afamin (AFAM), alpha-1-microglobulin (AMBP), apolipoprotein E (APOE), serum amyloid P-component (SAMP), histidine-rich glycoprotein (HRG) and alpha-1-antitrypsin (A1AT) were up-regulated and one, clusterin (CLUS), down-regulated. All nine proteins are known to be involved in foetal growth and development. APOE, SAMP, AFAM and CLUS are associated with the DS phenotype. Western blot and densitometric analysis of APOE and SAMP confirmed the increase of both proteins by 19 and 48% respectively.
CONCLUSIONS: All differentially expressed proteins are candidate biomarkers for DS, providing opportunities for the development of non-invasive prenatal diagnosis. As these are preliminary findings, follow-up experiments are needed for their evaluation. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551720     DOI: 10.1002/pd.2040

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  18 in total

1.  Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery.

Authors:  Roberto Romero; Shali Mazaki-Tovi; Edi Vaisbuch; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Ricardo Gomez; Jyh Kae Nien; Bo Hyun Yoon; Moshe Mazor; Jingqin Luo; David Banks; John Ryals; Chris Beecher
Journal:  J Matern Fetal Neonatal Med       Date:  2010-05-26

2.  Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal.

Authors:  P F Scholl; R N Cole; I Ruczinski; M Gucek; R Diez; A Rennie; C Nathasingh; K Schulze; P Christian; J D Yager; J D Groopman; K P West
Journal:  Placenta       Date:  2012-03-03       Impact factor: 3.481

Review 3.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 4.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

Review 5.  The Use of Proteomics in Assisted Reproduction.

Authors:  Ioanna Kosteria; Athanasios K Anagnostopoulos; Christina Kanaka-Gantenbein; George P Chrousos; George T Tsangaris
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

6.  Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Gary Siuzdak; Howard S Fox
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

7.  Non invasive prenatal diagnosis of aneuploidy: next generation sequencing or fetal DNA enrichment?

Authors:  A Webb; Te Madgett; T Miran; K Sillence; N Kaushik; M Kiernan; Nd Avent
Journal:  Balkan J Med Genet       Date:  2012-12       Impact factor: 0.519

8.  Gene expression profiling in a mouse model identifies fetal liver- and placenta-derived potential biomarkers for Down Syndrome screening.

Authors:  Jeroen L A Pennings; Wendy Rodenburg; Sandra Imholz; Maria P H Koster; Conny T M van Oostrom; Timo M Breit; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

9.  Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining.

Authors:  Jeroen L A Pennings; Maria P H Koster; Wendy Rodenburg; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

10.  Biomarker development for non-invasive prenatal diagnosis of fetal aneuploidies: predictive reliability and potential clinical application.

Authors:  Aggeliki Kolialexi; Athanasios K Anagnostopoulos; Georgia Tounta; Aris Antsaklis; Ariadni Mavrou; George Th Tsangaris
Journal:  EPMA J       Date:  2011-05-18       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.